FR2934955B1 - Encapsulation d'agents therapeutiques lipophiles ou amphiphiles dans des nanoemulsions - Google Patents

Encapsulation d'agents therapeutiques lipophiles ou amphiphiles dans des nanoemulsions

Info

Publication number
FR2934955B1
FR2934955B1 FR0855589A FR0855589A FR2934955B1 FR 2934955 B1 FR2934955 B1 FR 2934955B1 FR 0855589 A FR0855589 A FR 0855589A FR 0855589 A FR0855589 A FR 0855589A FR 2934955 B1 FR2934955 B1 FR 2934955B1
Authority
FR
France
Prior art keywords
nanoemulsions
lipophilic
encapsulation
therapeutic agents
amphiphilic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR0855589A
Other languages
English (en)
Other versions
FR2934955A1 (fr
Inventor
Robert Veronique Mourier
Jerome Bibette
Mathieu Goutayer
Y Garcia Fabrice Navarro
Nogues Isabelle Texier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Commissariat a lEnergie Atomique et aux Energies Alternatives CEA
Original Assignee
Commissariat a lEnergie Atomique CEA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0855589A priority Critical patent/FR2934955B1/fr
Application filed by Commissariat a lEnergie Atomique CEA filed Critical Commissariat a lEnergie Atomique CEA
Priority to US13/058,850 priority patent/US10092506B2/en
Priority to PCT/EP2009/060539 priority patent/WO2010018223A1/fr
Priority to CN200980138629.XA priority patent/CN102170866B/zh
Priority to CA2733963A priority patent/CA2733963C/fr
Priority to EP18153452.0A priority patent/EP3335698A1/fr
Priority to EP09781842.1A priority patent/EP2328554B1/fr
Priority to JP2011522520A priority patent/JP5981139B2/ja
Priority to ES09781842.1T priority patent/ES2671047T3/es
Publication of FR2934955A1 publication Critical patent/FR2934955A1/fr
Application granted granted Critical
Publication of FR2934955B1 publication Critical patent/FR2934955B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
FR0855589A 2008-08-14 2008-08-14 Encapsulation d'agents therapeutiques lipophiles ou amphiphiles dans des nanoemulsions Active FR2934955B1 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
FR0855589A FR2934955B1 (fr) 2008-08-14 2008-08-14 Encapsulation d'agents therapeutiques lipophiles ou amphiphiles dans des nanoemulsions
PCT/EP2009/060539 WO2010018223A1 (fr) 2008-08-14 2009-08-14 Encapsulation d'agents thérapeutiques lipophiles ou amphiphiles dans des nanoémulsions
CN200980138629.XA CN102170866B (zh) 2008-08-14 2009-08-14 亲脂性或两亲性治疗剂在纳米乳剂中的包囊
CA2733963A CA2733963C (fr) 2008-08-14 2009-08-14 Encapsulation d'agents therapeutiques lipophiles ou amphiphiles dans des nanoemulsions
US13/058,850 US10092506B2 (en) 2008-08-14 2009-08-14 Encapsulation of lipophilic or amphiphilic therapeutic agents in nano-emulsion
EP18153452.0A EP3335698A1 (fr) 2008-08-14 2009-08-14 Encapsulation d'agents thérapeutiques lipophiles ou amphiphiles dans des nanoémulsions
EP09781842.1A EP2328554B1 (fr) 2008-08-14 2009-08-14 Encapsulation d'agents photosensibilisateurs dans des nanoémulsions
JP2011522520A JP5981139B2 (ja) 2008-08-14 2009-08-14 親油性または両親媒性治療薬のナノエマルションへの封入
ES09781842.1T ES2671047T3 (es) 2008-08-14 2009-08-14 Encapsulado de fotosensibilizadores en nanoemulsiones

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0855589A FR2934955B1 (fr) 2008-08-14 2008-08-14 Encapsulation d'agents therapeutiques lipophiles ou amphiphiles dans des nanoemulsions

Publications (2)

Publication Number Publication Date
FR2934955A1 FR2934955A1 (fr) 2010-02-19
FR2934955B1 true FR2934955B1 (fr) 2011-07-08

Family

ID=40459260

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0855589A Active FR2934955B1 (fr) 2008-08-14 2008-08-14 Encapsulation d'agents therapeutiques lipophiles ou amphiphiles dans des nanoemulsions

Country Status (8)

Country Link
US (1) US10092506B2 (fr)
EP (2) EP3335698A1 (fr)
JP (1) JP5981139B2 (fr)
CN (1) CN102170866B (fr)
CA (1) CA2733963C (fr)
ES (1) ES2671047T3 (fr)
FR (1) FR2934955B1 (fr)
WO (1) WO2010018223A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2934954B1 (fr) 2008-08-14 2011-07-22 Commissariat Energie Atomique Emulsion fluorescente de vert d'indocyanine
FR2934953B1 (fr) 2008-08-14 2011-01-21 Commissariat Energie Atomique Nanoemulsions de nanocristaux
AU2011340797B2 (en) 2010-12-10 2017-08-10 Ns Technologies Pty Ltd Methods for forming miniemulsions and use thereof for delivering bioactive agents
WO2013008083A1 (fr) * 2011-07-13 2013-01-17 National Institute Of Pharmaceutical Education And Research (Niper) Composition pharmaceutique pouvant améliorer l'efficacité anticancéreuse du tamoxifène
FR2980972B1 (fr) 2011-10-05 2014-02-28 Commissariat Energie Atomique Formulations pour le diagnostic et le traitement de cancers hormonodependants et de cancers des organes de synthese d'hormones steroidiennes.
DE102011116069A1 (de) 2011-10-18 2013-04-18 Dr. Rimpler Gmbh Lipidnanopartikeldispersion, Verfahren zu deren Herstellung sowie ihre Verwendung
WO2013138520A1 (fr) * 2012-03-13 2013-09-19 University Of Tennessee Research Foundation Composition et système d'administration transdermique
FR2988608B1 (fr) * 2012-03-30 2014-09-05 Commissariat Energie Atomique Materiau, son procede de preparation et ses utilisations
FR2988609B1 (fr) * 2012-03-30 2015-09-04 Commissariat Energie Atomique Formulation pour l'hormonotherapie
FR2991196B1 (fr) * 2012-05-29 2014-06-27 Capsum Nanoparticules ciblantes pour une application biologique
US10253315B2 (en) 2012-08-30 2019-04-09 Commissariat A L'energie Atomique Et Aux Energies Alternatives Method for transfection of nucleic acids into eukaryotic cells in 3D scaffold
FR2994849B1 (fr) * 2012-08-30 2015-01-02 Commissariat Energie Atomique Formulation pour la delivrance de sequences nucleotidiques susceptibles de moduler des mecanismes endogenes d'arn interferents
FR2998899B1 (fr) 2012-11-30 2015-07-17 Commissariat Energie Atomique Methode de criblage a haut-debit pour l'identification de biomarqueurs, cibles therapeutiques ou d'agents therapeutiques
US9968673B2 (en) * 2013-02-26 2018-05-15 Commissariat á l'ènergie atomique et aux ènergies alternatives Immunogenic composition in emulsion form comprising two dispersed phases, one comprising an antigen and the other comprising an immunostimulating agent
FR3002454B1 (fr) 2013-02-26 2015-04-10 Commissariat Energie Atomique Composition immunogene sous forme d'emulsion
US10251837B2 (en) * 2014-02-14 2019-04-09 Jingjun Huang Compositions for nanoemulsion delivery systems
US11400048B2 (en) * 2014-06-25 2022-08-02 Synergia Bio Sciences Private Limited Pharmaceutical oil-in-water nano-emulsion
EP3103485A1 (fr) 2015-06-11 2016-12-14 Commissariat A L'energie Atomique Et Aux Energies Alternatives Matériau comprenant un polymère susceptible de former un hydrogel et des nanoparticules
EP3103482A1 (fr) 2015-06-11 2016-12-14 Commissariat à l'Énergie Atomique et aux Énergies Alternatives Matériau comprenant du collagène dont les fibres sont revêtues de nanoparticules
WO2017085248A1 (fr) * 2015-11-18 2017-05-26 Commissariat à l'énergie atomique et aux énergies alternatives Composition immunogène sous forme d'émulsion comprenant deux phases dispersées, l'une comprenant un antigène et l'autre comprenant un agent immunostimulant
FR3043558B1 (fr) * 2015-11-18 2017-12-29 Commissariat Energie Atomique Composition immunogene sous forme d'emulsion comprenant deux phases dispersees, l'une comprenant un antigene et l'autre comprenant un agent immunostimulant
PL3225112T3 (pl) * 2016-04-01 2022-01-03 Trioptotec Gmbh Dyspersja fotouczulacza i jej zastosowanie
KR101901986B1 (ko) * 2016-11-18 2018-09-27 서울대학교산학협력단 암세포의 선택적 형광 표지를 위한 나노전달체 및 그 제조방법
CA3121253A1 (fr) * 2018-11-27 2020-06-04 Avignon Universite Procede d'extraction de substances d'interet

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL78929A0 (en) 1985-07-29 1986-09-30 Abbott Lab Microemulsion compositions for parenteral administration
US4906100A (en) 1988-05-13 1990-03-06 University Of Cincinnati Method of detecting adriamycin (doxorubicin) or daunomycin in the environment
EP0449960B1 (fr) 1988-12-20 1993-09-08 Medicontrol Corporation Compositions d'emulsions deshydratees a la chaleur
CH677886A5 (fr) 1989-06-26 1991-07-15 Hans Georg Prof Dr Weder
JP2785981B2 (ja) 1989-11-20 1998-08-13 株式会社資生堂 乳化組成物
GB2251381B (en) 1990-07-19 1995-01-25 Charwell Pharma Emulsified fluorescein diester diagnostic compositions
US5403575A (en) 1991-12-12 1995-04-04 Hemagen/Pfc Highly fluorinated, chloro-substituted organic compound-containing emulsions and methods of using them
FR2685636B1 (fr) * 1991-12-31 1995-03-24 Gattefosse Ets Sa Excipient pour suppositoire constitue par une microemulsion et procede pour le fabriquer.
IL101007A (en) 1992-02-18 1997-08-14 Pharmos Ltd Dry stable compositions prepared by lyophilization
IL101387A (en) 1992-03-26 1999-11-30 Pharmos Ltd Emulsion with enhanced topical and/or transdermal systemic effect utilizing submicron oil droplets
US5464696A (en) 1992-08-13 1995-11-07 Bracco International B.V. Particles for NMR imaging
JPH08506081A (ja) 1993-02-12 1996-07-02 ファーモス コーポレイション サブミクロン・エマルジョンの調製のための乾燥組成物
CA2091152C (fr) 1993-03-05 2005-05-03 Kirsten Westesen Particules lipidiques solides, particules d'agents bioactifs, et methode de preparation et d'utilisation
US6113921A (en) 1993-03-23 2000-09-05 Pharmos Corp. Topical and transdermal delivery system utilizing submicron oil spheres
FR2721210B1 (fr) 1994-06-17 1996-08-02 Oreal Composition de nettoyage contenant des grains lipidiques.
US6540981B2 (en) 1997-12-04 2003-04-01 Amersham Health As Light imaging contrast agents
WO1998048838A1 (fr) 1997-04-29 1998-11-05 Nycomed Imaging As Composes
EP0979107A1 (fr) 1997-04-29 2000-02-16 Nycomed Imaging As Agents de contraste utilises dans des techniques d'imagerie basees sur la lumiere
GB9712525D0 (en) 1997-06-16 1997-08-20 Nycomed Imaging As Method
GB9721746D0 (en) 1997-10-15 1997-12-10 Panos Therapeutics Limited Compositions
US5976502A (en) 1997-10-21 1999-11-02 Gholam A. Peyman Method of visualizing particles and blood cells containing a fluorescent lipophilic dye in the retina and choroid of the eye
US6123923A (en) 1997-12-18 2000-09-26 Imarx Pharmaceutical Corp. Optoacoustic contrast agents and methods for their use
TW537894B (en) 1998-05-26 2003-06-21 Novartis Ag A spontaneously dispersible pharmaceutical composition comprising a piperidine substance P antagonist
DE19852245A1 (de) * 1998-11-12 2000-05-18 Asat Ag Applied Science & Tech 5-Aminolävulinsäure-Nanoemulsion
FR2787326B1 (fr) 1998-12-17 2001-01-26 Oreal Nanoemulsion a base d'esters gras de glycerol, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
FR2788007B1 (fr) 1999-01-05 2001-02-09 Oreal Nanoemulsion a base de copolymeres blocs d'oxyde d'ethylene et d'oxyde de propylene, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
US20020102301A1 (en) 2000-01-13 2002-08-01 Joseph Schwarz Pharmaceutical solid self-emulsifying composition for sustained delivery of biologically active compounds and the process for preparation thereof
FR2805761B1 (fr) * 2000-03-02 2002-08-30 Mainelab Nanocapsules lipidiques, procede de preparation et utilisation comme medicament
AU2002357012A1 (en) 2001-11-27 2003-06-10 Transform Pharmaceuticals, Inc. Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
AU2004263136A1 (en) * 2003-08-08 2005-02-17 Barnes-Jewish Hospital Emulsion particles for imaging and therapy and methods of use thereof
FR2860717B1 (fr) 2003-10-13 2006-02-03 Ethypharm Sa Compositions de particules lipidiques solides monodisperses
FR2861986B1 (fr) 2003-11-07 2007-12-14 Oreal Composition de maquillage comprenant une emulsion
EP1563851A1 (fr) 2004-02-17 2005-08-17 Yissum Research Development Company of the Hebrew University of Jerusalem Emulsions cationiques ciblées avec des anticorps pour la livraison de drogues
CN1676125A (zh) * 2004-03-31 2005-10-05 张昊 含有紫杉碱类或难溶药物的纳米级乳剂
US20050255044A1 (en) 2004-05-14 2005-11-17 Lomnes Stephen J Contrast agent for combined modality imaging and methods and systems thereof
US8557861B2 (en) 2004-09-28 2013-10-15 Mast Therapeutics, Inc. Low oil emulsion compositions for delivering taxoids and other insoluble drugs
ITMI20050218A1 (it) 2005-02-15 2006-08-16 Maycos Italiana Di Comini Miro Nanoemulsioni comprendenti lipoamminoacidi monogliceridi digliceridi poligliceridi degli acidi grassi
ATE382677T1 (de) 2005-02-18 2008-01-15 Gnosis Spa Verfahren zur herstellung von hefe-mikrokapseln
US20060222716A1 (en) * 2005-04-01 2006-10-05 Joseph Schwarz Colloidal solid lipid vehicle for pharmaceutical use
US20060257493A1 (en) * 2005-04-28 2006-11-16 Amiji Mansoor M Nanoparticulate delivery systems for treating multi-drug resistance
US20070148194A1 (en) 2005-11-29 2007-06-28 Amiji Mansoor M Novel nanoemulsion formulations
WO2008042841A2 (fr) * 2006-10-02 2008-04-10 Dr. Reddy's Laboratories Limited Compositions du docétaxel
WO2008102065A1 (fr) * 2007-02-14 2008-08-28 Commissariat A L'energie Atomique Emulsions fluorescentes pour l'imagerie optique
EP1985298A1 (fr) * 2007-04-24 2008-10-29 Azad Pharma AG Émulsions ophtalmiques eau dans l'huile contenant des prostaglandines
KR101469026B1 (ko) * 2007-12-11 2014-12-05 삼성디스플레이 주식회사 표시 장치 및 그 표시판의 제조 방법
FR2934953B1 (fr) 2008-08-14 2011-01-21 Commissariat Energie Atomique Nanoemulsions de nanocristaux
FR2935001B1 (fr) 2008-08-14 2011-12-30 Commissariat Energie Atomique Emulsion fluorescente
FR2934954B1 (fr) * 2008-08-14 2011-07-22 Commissariat Energie Atomique Emulsion fluorescente de vert d'indocyanine

Also Published As

Publication number Publication date
CA2733963C (fr) 2017-02-21
CN102170866A (zh) 2011-08-31
CN102170866B (zh) 2014-09-17
CA2733963A1 (fr) 2010-02-18
EP2328554B1 (fr) 2018-03-14
FR2934955A1 (fr) 2010-02-19
JP5981139B2 (ja) 2016-08-31
US20110201695A1 (en) 2011-08-18
US10092506B2 (en) 2018-10-09
EP3335698A1 (fr) 2018-06-20
JP2012504107A (ja) 2012-02-16
ES2671047T3 (es) 2018-06-04
EP2328554A1 (fr) 2011-06-08
WO2010018223A1 (fr) 2010-02-18

Similar Documents

Publication Publication Date Title
FR2934955B1 (fr) Encapsulation d'agents therapeutiques lipophiles ou amphiphiles dans des nanoemulsions
WO2010018216A3 (fr) Émulsion fluorescente de vert d'indocyanine
BRPI0700148A (pt) emulsões cosméticas de baixa viscosidade e estabilidade prolongada, de preparação a frio
AR060163A1 (es) Micelas de proteina de suero
WO2006074177A3 (fr) Composition de microemulsion sans alcool
EE200300109A (et) Protsess vedela emulsioonkompositsiooni valmistamiseks ja emulsiooni kontsentraadi valmistamiseks, farmatseutiline kompositsioon, emulsiooni kontsentraat, komplekt ja emulsioonkompositsioon
MXPA05002814A (es) Formulacion para agentes lipofilicos.
TW200613004A (en) External preparation of solid/oil type
HUP0001775A2 (hu) Testtisztító szer
TW200744677A (en) Compositions and methods for preparation of poorly water soluble drugs with increased stability
ZA200608200B (en) Microfluidized oil-in-water emulsions and vaccine compositions
CL2008000565A1 (es) Concentrado envasado para preparar un consome, caldo, sopa, salsa o para su uso como condimento que comprende 20 a 80% en peso de agua, 1 a 4% de un agente gelante que contiene goma xantano y goma guar, 15 a 40% de sal y 0,5 a 60% de componentes que
AR062655A1 (es) Formulaciones de emulsiones de pickering
RS20090096A (sr) Formulacije pickering emulzije
CL2008000567A1 (es) Concentrado envasado para preparar un consome, caldo, sopa, salsa o para su uso como condimento que comprende 20 a 80% en peso de agua, 0,8 a 4% de un agente gelificante que contiene manano de konjac, 15 a 40% de sal y 0,5 a 60% de componentes que im
ATE500835T1 (de) Entzündungshemmende zusammensetzungen und anwendungsverfahren
WO2008070141A3 (fr) Compositions pour administrer des agents thérapeutiques
HUP0402318A2 (hu) Ciklosporint tartalmazó gyógyászati készítmény és alkalmazása
EP2251004A3 (fr) Composition pharmaceutique ou cosmétique, et procédé de solubilisation mixte pour préparer la composition
FR3086172B1 (fr) Formulation cosmetique
GB2434363B (en) Amphiphilic nanotubes and micelles comprising them for use in the delivery of biologically active agents
CL2009000390A1 (es) Composicion liquida de limpieza que comprende 1-30% en surfactante anionico, hasta 5% en surfactante anfotero, 2% de electrolito, 5% de surfactante monoalcanolamida y entre 50-94,5% de agua; kit; uso.
FR2978661B1 (fr) Composition lipidique pour application cosmetique
MA32626B1 (fr) Composition cosmetique comprenant un extrait d'acanthe et utilisation d'acanthe dans une composition cosmetique capillaire
WO2012039768A3 (fr) Formulations d'itraconazole

Legal Events

Date Code Title Description
CA Change of address
CD Change of name or company name
PLFP Fee payment

Year of fee payment: 9

PLFP Fee payment

Year of fee payment: 10

PLFP Fee payment

Year of fee payment: 11

PLFP Fee payment

Year of fee payment: 12

PLFP Fee payment

Year of fee payment: 13

PLFP Fee payment

Year of fee payment: 14

PLFP Fee payment

Year of fee payment: 15

PLFP Fee payment

Year of fee payment: 16